Wastewater remediation of pharmaceuticals with ozone and granular active carbon: a risk-driven approach

利用臭氧和颗粒活性炭处理药物废水:一种风险驱动方法

阅读:1

Abstract

This study aimed to investigate the removal efficiency of (psycho)pharmaceuticals by ozonation and granular active carbon (GAC) in wastewater effluent, using risk as the metric for adequate removal instead of aqueous concentrations. Conventionally treated effluent was further treated with ozone or GAC until there was a 25% reduced UVA(254) absorbance, to allow for a direct comparison of the two treatment types. Samples were analysed using Ultra High-Performance Liquid Chromatography-Quadrupole Time of Flight-High Resolution Mass Spectrometry (UHPLC-qTOF-HRMS), where 20 (psycho)pharmaceuticals were quantified, and their risk was assessed using Predicted No Effect Concentrations (PNECs). A further assessment was performed using Quantitative Structural Activity Relationships (QSARs) for both parent compounds and their Oxidation Transformation Products (OTPs) to compare the relative toxicity of new species being formed by the ozone treatment. The total median removal efficiency across all compounds was 60 ± 3% for ozone in terms of concentration, yielding a 73 ± 2% reduction in terms of risk for the parent compounds, while the median removal efficiency for GAC is 57 ± 9% as expressed in concentration, and 46 ± 11% in terms of risk reduction. When factoring in the OTP toxicity, the median risk reduction for ozone flips to -274 ± 124%, indicating that there may be an increase in risk during ozonation. Pearson correlations on molecular descriptors indicated that ozone removal most strongly correlated with the number of activated aromatic rings (r = 0.65), while for GAC the topological polar surface area correlated strongest with removal (r = 0.54), therefore indicating that ozone and GAC target different types of molecules. The study demonstrates the merits of a risk-driven approach over concentration-based removal targets in current legislation, but also highlighted some drawbacks, especially with regards to data gaps and model accuracies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。